Introduction of delegated executive officer system effective April 1, 2026, and implementation of executive officer personnel changes. CEO Yutaka Ogihara continues in his role.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4569","jir_company_name":"Kyorin Pharmaceutical Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-02-26","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4569-20260226-01.pdf","jir_short_summary":"Introduction of delegated executive officer system effective April 1, 2026, and implementation of executive officer personnel changes. CEO Yutaka Ogihara continues in his role.","jir_summary":"### About the Introduction of the Delegated Executive Officer System\nKyorin Pharmaceutical Co., Ltd. will introduce a delegated executive officer system in addition to the existing employment-type executive officer system, effective April 1, 2026, aiming to strengthen corporate governance. Delegated executive officers will be limited to senior executive officers and above. Directors may concurrently serve as executive officers, promoting the separation of decision-making and supervisory functions from business execution functions, with the goal of enhancing management soundness and transparency.\n\n### Regarding Executive Officer Personnel Changes\nIn the personnel changes effective April 1, 2026, Yutaka Ogihara will continue as Representative Director President CEO. Directors Michio Onoda and Yasushi Kurose will be appointed as senior executive officers. Takaaki Kaji, Noriaki Tamura, Junichi Ishiyama, and Takeo Uehara will be promoted to senior executive officers as delegated executive officers and appointed heads of their respective divisions. Additionally, new employment-type executive officers will be appointed, and some changes made to their responsibilities to strengthen the organizational structure.","jir_financial_highlights":"Implementation Date: 2026-04-01 (New system introduction)\nRepresentative Director President CEO: Yutaka Ogihara (Continuing)\nSenior Executive Officers: Multiple individuals (Takaaki Kaji, Noriaki Tamura, Junichi Ishiyama, Takeo Uehara) (Appointed as newly established delegated executive officers)","jir_category":"","jir_hashtags":"#KyorinPharmaceutical, #executive_change, #JapaneseStocks","jir_key_figures":"Delegated Executive Officer System Introduction Date: 2026-04-01\nRepresentative Director President CEO: Yutaka Ogihara (Continuing)\nNumber of Senior Executive Officers (Delegated Type) Appointed: 4","jir_meta_title":"Kyorin Pharmaceutical Introduces Delegated Executive Officer System and Implements Executive Officer Personnel Changes in April 2026","jir_meta_description":"Kyorin Pharmaceutical announces the introduction of a delegated executive officer system effective April 1, 2026, along with executive officer personnel changes. CEO Yutaka Ogihara continues, strengthening the organizational structure.","jir_og_title":"Kyorin Pharmaceutical Announces Introduction of Delegated Executive Officer System and Personnel Changes","jir_og_description":"Effective April 1, 2026, the introduction of the delegated executive officer system and executive officer personnel changes will enhance management transparency and soundness.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":16660,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"executive_change","footnotes":""},"sector":[],"importance":[],"class_list":["post-31359","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n